OPHLY OTC

Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents. Its current portfolio features a range of established treatments, notably in oncology, with products such as the intravenous infusions OPDIVO and KYPROLIS, alongside MEKTOVI, VELEXBRU, ADLUMIZ (tablets), and BRAFTOVI (capsules) for various malignant tumors. Other specialized oncology support includes EMEND capsules and PROEMEND intravenous injections to manage chemotherapy-induced nausea and vomiting, and DEMSER capsules for symptomatic improvement in pheochromocytoma patients. Beyond cancer, Ono offers therapies for prevalent conditions like type 2 diabetes (GLACTIV and FORXIGA tablets), chronic heart failure (CORALAN), and various inflammatory and neurological disorders. Specific offerings in these areas include ONOACT injections for tachyarrhythmia, OPALMON tablets for peripheral circulatory issues, ORENCIA injections for rheumatoid arthritis, RIVASTACH patches for Alzheimer's disease, and ONGENTYS tablets for Parkinson's disease. The company also addresses needs in renal care with PARSABIV intravenous injections for dialysis patients, urological health with STAYBLA tablets for overactive bladder, and respiratory conditions with ONON capsules and dry syrups for bronchial asthma and allergic rhinitis. Furthermore, its offerings extend to musculoskeletal health with JOYCLU intra-articular injections for improving joint function, and RECALBON tablets for osteoporosis. Ono Pharmaceutical is also deeply invested in future medical advancements, with an extensive pipeline of products under development. This pipeline targets a wide array of diseases, encompassing numerous types of cancer, including esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, and myelodysplastic syndrome, as well as addressing virus positive/negative solid carcinoma. Beyond oncology, their research extends to inflammatory and autoimmune disorders such as polymyositis/dermatomyositis, pemphigus, generalized scleroderma, and enthesopathy. They are also developing treatments for conditions affecting the cardiovascular and nervous systems, including tachyarrhythmia, diabetic polyneuropathy, neurodegenerative diseases, narcolepsy, and thrombosis. Established in 1717, Ono Pharmaceutical Co., Ltd. maintains its headquarters in Osaka, Japan.